News and Updates

Amylyx reports success in a Phase III trial for its $35M-acquired drug, hitting key efficacy endpoints. Learn what this means for future treatment options.

Considering a clinical trial? Learn the essential facts, eligibility requirements, and logistical hurdles you need to know before enrolling in research.

Are high-dose cancer treatments doing more harm than good? Discover why researchers and the FDA are shifting toward smarter, safer precision dosing.

Experts are scrutinizing Huidagene’s trial protocols following a participant's death, highlighting critical safety concerns in gene editing research.

Discover how CRO acquisitions impact clinical trial sites and learn vital strategies for sponsors to maintain data integrity during organizational shifts.

New Phase 3 data for upadacitinib shows promise in treating vitiligo, signaling a major shift in JAK inhibitor therapy for autoimmune skin conditions.

China has approved satricabtagene autoleucel, a new CAR-T therapy targeting CLDN18.2 for advanced gastric cancer. Learn about this breakthrough for patients.

Curavit bolsters its global clinical trial capabilities by acquiring Lindus Health assets, bridging U.S. and European decentralized research operations.

New Phase 3 data reveals avexitide effectively treats post-bariatric hypoglycemia, offering a potential breakthrough for patients with blood sugar issues.

A new Indian pharmaceutical policy aims to boost domestic production but raises concerns about the potential price surge of essential, life-saving drugs.